Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease

Journal of the National Cancer Institute

Volumn 95, Issue 13, 2003, Pages 971-980

  van Leeuwen, Flora E ^a   Klokman, Willem J ^a   Stovall, Marilyn ^b   Dahler, Ellen C ^a   van't Veer, Mars B ^c   Noordijk, Evert M ^d   Crommelin, Mariad A ^e   Aleman, Berthe M P ^a   Broeks, Annegien ^a   Gospodarowicz, Mary ^f   Travis, Lois B ^g   Russell, Nicola S ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF TEXAS   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e CATHARINA HOSPITAL   (Netherlands)

^f UNIVERSITY OF TORONTO   (Canada)

^g NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CHLORMETHINE; PROCARBAZINE; SEX HORMONE;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HODGKIN DISEASE; HORMONE ACTION; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MENOPAUSE; NETHERLANDS; PATIENT INFORMATION; PRIORITY JOURNAL; RADIATION DOSE; REPRODUCTION; RISK ASSESSMENT; STATISTICAL ANALYSIS; TUMOR LOCALIZATION;

EID: 0041963074     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/95.13.971     Document Type: Article

References (56)

1. Aisenberg AC, Finkelstein DM, Doppke KP, Koerner FC, Boivin JF, Willett CG. High risk of breast carcinoma after irradiation of young women with Hodgkin's disease. Cancer 1997;79:1203-10.
2. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996;334:745-51.
3. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev 2000;26:291-302.
4. Cutuli B, Borel C, Dhermain F, Magrini SM, Wasserman TH, Bogart JA, et al. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol 2001;59:247-55.
5. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31.
6. Mauch PM, Kalish LA, Marcus KC, Coleman CN, Shulman LN, Krill E, et al. Second malignancies after treatment for laparotomy staged IA-IIIB Hodgkin's disease: long-term analysis of risk factors and outcome. Blood 1996;87:3625-32.
7. Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, et al. Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18:2435-43.
8. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618-29.
9. Sankila R, Garwicz S, Olsen JH, Dollner H, Hertz H, Kreuger A, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 1996;14:1442-6.
10. Travis LB, Curtis RE, Boice Jr JD. Late effects of treatment for childhood Hodgkin's disease. N Engl J Med 1996;335:352-3.
11. van Leeuwen FE, Klokman WJ, van't Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000;18:487-97.
12. Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS. Second cancers following pediatric Hodgkin's disease. J Clin Oncol 1998;16:536-44.
13. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18:498-509.
14. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-94.
15. van Leeuwen FE, Swerdlow AJ, Valagussa P, Tucker MA. Second cancers after treatment of Hodgkin's disease. In: Mauch PM, Armitage JO, Diehl V, Hoppe RT, Weiss LM, editors. Hodgkin's disease. Philadelphia (PA): Lippincott Williams & Wilkins; 1999. p. 607-32.
16. Boice Jr JD, Preston D, Davis FG, Monson RR. Frequent chest X-ray fluoroscopy and breast cancer incidence among tuberculosis patients in Massachusetts. Radiat Res 1991;125:214-22.
17. Hildreth NG, Shore RE, Dvoretsky PM. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989;321:1281-4.
18. Lundell M, Mattsson A, Karlsson P, Holmberg E, Gustafsson A, Holm LE. Breast cancer risk after radiotherapy in infancy: a pooled analysis of two Swedish cohorts of 17,202 infants. Radiat Res 1999;151:626-32.
19. Mattsson A, Ruden BI, Hall P, Wilking N, Rutqvist LE. Radiation-induced breast cancer: long-term follow-up of radiation therapy for benign breast disease. J Natl Cancer Inst 1993;85:1679-85.
20. Shore RE, Hildreth N, Woodard E, Dvoretsky P, Hempelmann L, Pasternack B. Breast cancer among women given X-ray therapy for acute postpartum mastitis. J Natl Cancer Inst 1986;77:689-96.
21. Tokunaga M, Land CE, Tokuoka S, Nishimori I, Soda M, Akiba S. Incidence of female breast cancer among atomic bomb survivors, 1950-1985. Radiat Res 1994;138:209-23.
22. Boice Jr JD. Radiation and breast carcinogenesis. Med Pediatr Oncol 2001;36:508-13.
23. Little MP, Weiss HA, Boice Jr JD, Darby SC, Day NE, Muirhead CR. Risks of leukemia in Japanese atomic bomb survivors, in women treated for cervical cancer, and in patients treated for ankylosing spondylitis. Radiat Res 1999;152:280-92.
24. Preston DL, Mattsson A, Holmberg E, Shore R, Hildreth NG, Boice Jr JD. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res 2002;158:220-35.
25. Tinger A, Wasserman TH, Klein EE, Miller EA, Roberts T, Piephoff JV, et al. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys 1997;37:865-70.
26. Yahalom J, Petrek JA, Biddinger PW, Kessler S, Dershaw DD, McCormick B, et al. Breast cancer in patients irradiated for Hodgkin's disease: a clinical and pathologic analysis of 45 events in 37 patients. J Clin Oncol 1992;10:1674-81.
27. Sont JK, van Stiphout WA, Noordijk EM, Molenaar J, Zwetsloot-Schonk JH, Willemze R, et al. Increased risk of second cancers in managing Hodgkin's disease: the 20-year Leiden experience. Ann Hematol 1992;65:213-8.
28. van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol 1994;12:312-25.
29. van Spronsen DJ, Post PN, Crommelin MA, Breed WP, Coebergh JW. Modest decline in late mortality following Hodgkin's disease in the southeastern Netherlands since 1972. Ann Hematol 1998;76:205-9.
30. Broeks A, Russell NS, Floore AN, Urbanus JH, Dahler EC, van't Veer MB, et al. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int J Radiat Biol 2000; 76:693-8.
31. Stovall M, Shalek RJ. Physics contribution to radiology in brachytherapy. Med Phys 1995;22:1907-9.
32. Stovall M, Smith SA, Rosenstein M. Tissue doses from radiotherapy of cancer of the uterine cervix. Med Phys 1989;16:726-33.
33. Breslow NE, Day NE. Statistical methods in cancer research. Vol. I. The analysis of case-control studies. IARC Sci Publ 1980;32:248-79.
34. Cytel Software Corp. EGRET for windows version 2.0.31. Cambridge (MA): Cytel Software Corp.; 2002.
35. Tucker MA. Solid second cancers following Hodgkin's disease. Hematol Oncol Clin North Am 1993;7:389-400.
36. Boice JD Jr, Stone BJ. Interaction between radiation and other breast cancer risk factors. In: Late biological effects of ionizing radiation. Vienna (Austria): International Atomic Energy Agency; 1978. p. 231-47.
37. Little MP, Boice JD Jr. Comparison of breast cancer incidence in the Massachusetts tuberculosis fluoroscopy cohort and in the Japanese atomic bomb survivors. Radiat Res 1999;151:218-24.
38. Christie DR, Wills R, Drew JF, Barton MB. The doses received by the breast during mantle radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:223-6.
39. Kowalski A, Smith S. Measurement of radiation dose delivered to breast tissue during mantle field irradiation for Hodgkin's disease. Med Dosim 1998;23:31-6.
40. Rajaratnam S, Nisce LZ, Avanzato J. Dose to breast in breast undergoing mantle treatments. Med Dosim 1994;19:145-6.
41. Zellmer DL, Wilson JF, Janjan NA. Dosimetry of the breast for determining carcinogenic risk in mantle irradiation. Int J Radiat Oncol Biol Phys 1991;21:1343-51.
42. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-92.
43. Gervais-Fagnou DD, Girouard C, Laperriere N, Pintillie M, Goss PE. Breast cancer in women following supradiaphragmatic irradiation for Hodgkin's disease. Oncology 1999;57:224-31.
44. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13.
45. Andrieu JM, Ochoa-Molina ME. Menstrual cycle, pregnancies and offspring before and after MOPP therapy for Hodgkin's disease. Cancer 1983;52:435-8.
46. Homing SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981;304:1377-82.
47. Schilsky RL, Sherins RJ, Hubbard SM, Wesley MN, Young RC, DeVita VT. Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med 1981;71:552-6.
48. Waxman JH, Terry YA, Wrigley PF, Malpas JS, Rees LH, Besser GM, et al. Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. Br Med J (Clin Res Ed) 1982;285:1612-3.
49. Kreuser ED, Felsenberg D, Behles C, Seibt-Jung H, Mielcarek M, Diehl V, et al. Long-term gonadal dysfunction and its impact on bone mineralization in patients following COPP/ABVD chemotherapy for Hodgkin's disease. Ann Oncol 1992;3 Suppl 4:105-10.
50. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1997;350:1047-59.
51. Land CE, Hayakawa N, Machado SG, Yamada Y, Pike MC, Akiba S, et al. A case-control interview study of breast cancer among Japanese A-bomb survivors. II. Interactions with radiation dose. Cancer Causes Control 1994; 5:167-76.
52. Shore RE, Woodard ED, Hempelmann LH, Pasternack BS. Synergism between radiation and other risk factors for breast cancer. Prev Med 1980; 9:815-22.
53. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin's disease. JAMA. In press 2003.
54. Canellos GP. New treatments for advanced Hodgkin's disease: an uphill fight beginning close to the top. J Clin Oncol 2002;20:607-9.
55. Goss PE, Sierra S. Current perspectives on radiation-induced breast cancer. J Clin Oncol 1998;16:338-47.
56. Diller L, Nancarrow CM, Shaffer K, Matulonis U, Mauch P, Neuberg D. Breast cancer screening in women previously treated for Hodgkin's disease a prospective cohort study. J Clin Oncol 2002;20:2085-91.